钠-葡萄糖协同转运蛋白2抑制剂(sodium-dependent glucose transporters 2 inhibitor,SGLT-2)是一种新型口服降糖药物,目前在国内上市的SGLT-2抑制剂包括达格列净、恩格列净、卡格列净和艾托格列净。 列净类药物不同于传统的降糖药,不会引起低血糖风险,还具有减重、降压、降尿酸的效果[2],能够减少蛋白尿排泄,并可显...
肠促胰素治疗药物的差别 基于肠促胰素治疗的发展经历了80多年时间 GLP-1被发现发展为治疗2型糖尿病的药物确定促胰岛素分泌的效应定义肠促胰素肠促胰素及肠－胰素轴进一步被定义 命名‘肠－胰素轴’193019601970 发现exendin-4 肠促胰素治疗临床药物获批* 198019871990 2000 20092012 GLP-1发现25周年 肠促胰素在正常...
peplidase4inhibitor 肠促胰素,包括胰升糖素样肽1(GLP一1)和肠抑胃 肽(GIP),在维持血糖稳定方面起关键作用。临床研 究表明,肠促胰素可刺激胰岛素分泌,抑制胰升糖素分 泌,这些作用均依赖于葡萄糖。GLP一1还可延缓进食 后的胃排空速度,抑制食欲,减少进食量。据报道,在 临床前研究中,肠促胰素可促进B细胞复制...
32. Xu Y, Fu EL, Clase CM, Mazhar F, Jardine MJ, Carrero JJ. GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. Kidney Int 2022;101:36...
Hu Y,Liu HB,Simpson RW,Dear AE.GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells[J]. Molecular Biology Reports .2013(3)Hu Y, Liu H, Simpson RW et al. GLP-1-dependent and independent effects and molecular ...
cardiovascular biomarkers. The specific biomarkers focused on were adiponectin, leptin, IL-6, TNF-α, plasminogen activator inhibitor-1 (PAI-1), brain natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP). Increased levels of PAI-1 and BNP were found post-14-week ...
Accordingly, people with type 2 diabetes, cardiovascular disease, heart failure, or chronic kidney disease should be treated appropriately with an SGLT-2 inhibitor or GLP-1RA, even because more adults with type 2 diabetes in the US have suboptimal glycemic control now compared to 10 years ago, ...
DPP-4 inhibitorGLP-1 mimeticG-protein coupled receptor agonistperoxisome proliferator-activated receptor agonistSGLT2 inhibitorWhy should researchers in charge of... DJA Moraes,DB Zoccal,BH Machado - 《Hypertension》 被引量: 77发表: 2013年 Fatty liver disease in diabetes mellitus (GLP-1) analogs...
JAMA Netw Open. 2022 Mar 1;5(3):e221169 Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/35254430/...
The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo Article Open access 28 June 2017 Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease Article Open acces...